VET3-TGI Generates Responses in Checkpoint Inhibitor-Refractory Cutaneous Cancers

The phase 1/1b STEALTH-001 trial reports that the oncolytic virus VET3-TGI shows promise in treating advanced solid tumors, particularly in patients with checkpoint inhibitor-refractory cutaneous cancers. The study observed significant response rates in both injected and non-injected lesions with no dose-limiting toxicities.
Why it matters
This therapy offers a potential breakthrough for patients who have failed standard immunotherapy, addressing a critical unmet need in oncology.
Intratumoral administration of the oncolytic vaccinia virus VET3-TGI, given alone or in combination with atezolizumab (Tecentriq), generated responses in patients with advanced solid tumors, with activity concentrated in those with immune checkpoint inhibitor–refractory cutaneous malignancies, according to findings from the phase 1/1b STEALTH-001 trial (NCT06444815) presented at the 2026 SITC Annual Meeting.1,2
Responses occurred in both injected and non-injected lesions, and no dose-limiting toxicities (DLTs) were reported.
Findings showed that efficacy-evaluable patients (n = 12) treated intratumorally achieved an objective response rate (ORR) by blinded independent central review of 42%, including 1 complete response (CR) and 4 partial responses (PRs); the disease control rate was 75%.1
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in